Please use this identifier to cite or link to this item:
|Title:||Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia.|
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Proprotein Convertase 9
|Citation:||Adv Ther.2017 08;(34)8:1876-1896|
|Abstract:||Suboptimal drug adherence represents a major challenge to effective primary and secondary prevention of cardiovascular disease. While adherence is influenced by multiple considerations, polypharmacy and dosing frequency appear to be rate-limiting factors in patient satisfaction and subsequent adherence. The cardiovascular and metabolic therapeutic areas have recently benefited from a number of advances in drug therapy, in particular protease proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incretin-based therapies, respectively. These drugs are administered subcutaneously and offer efficacious treatment options with reduced dosing frequency. Whilst patients with diabetes and diabetologists are well initiated to injectable therapies, the cardiovascular therapeutic arena has traditionally been dominated by oral agents. It is therefore important to examine the practical aspects of treating patients with these new lipid-lowering agents, to ensure they are optimally deployed in everyday clinical practice.|
|Appears in Collections:||Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.